Use of full-face masks and helmets

2017-06-01
Andreas Freitag

Full-face masks or helmets are not used universally in everyday practice. What is your experience with using such devices? Do you use them often in your practice? Which patients would benefit most from this type of intervention?

Andreas Freitag: We use it often because a large proportion of our patients are overweight and a lot of times the masks are designed for much smaller faces, so it does not work, it does not fit on their nose, does not fit in the whole area here. Oftentimes the patients are bigger individuals and they feel less claustrophobic with a face mask.

We have respiratory therapists and we work with them. We tell the patients that we are going to try this intervention. We hopefully try to explain to them: do not feel claustrophobic, do not get scared, this is going to help you breathe, you are going to feel as if you are in a sort of a wind tunnel, or you are actually feeling the wind coming to your face. So we use [full-face masks], not uncommonly, especially in heavyset individuals.

We do not use the helmets very often, though. Once again, it is that it is difficult to monitor the patients when you are having the helmet on. It is hard to visualize or see what is going on with the patients. I think claustrophobia is a real issue for a lot of these patients. So we do not use the helmets very often, if at all. But we definitely use the full-face masks.

See also
  • Treatment of latent TB infection in patients with rheumatoid arthritis The WHO advocates several regimens for the treatment of latent tuberculosis (TB) infection. Are there any new data comparing different treatments that suggest which regimen would be optimal for adults with rheumatoid arthritis (RA) who have been treated for latent TB infection before starting biologic therapy for RA?
  • Nintedanib and pirfenidone in patients with FVC <50% What is your opinion on using nintedanib and pirfenidone in patients with forced vital capacity <50%? Are there any data available to support such treatment?
  • Idiopathic pulmonary fibrosis and troublesome cough What management would you recommend in a patient with IPF and troublesome cough? A study published some time ago suggested thalidomide was effective in the treatment of cough in patients with IPF. Is it used for this indication outside clinical trials?
  • Testing for latent TB infection in vaccinated populations In Poland, a significant proportion of cases of tuberculosis (TB) is latent TB infection, and most of the population has been vaccinated against TB. Is there still a place for tuberculin skin testing or should it be replaced with IGRAs?
  • Computed tomography as an initial study in suspected CAP A recently published paper discussed the use of CT as an initial study in patients presenting with suspected community-acquired pneumonia. The results were encouraging but not game-changing. When could a clinician consider CT in an outpatient presenting with symptoms of CAP?
  • ECMO in acute respiratory failure A lecture by Prof. Lars Broman delivered at the Challenges and Opportunities in Caring for Critically Ill conference in Kraków in 2015.

We would love to hear from you

Comments, mistakes, suggestions?